Log in
Enquire now
‌

US Patent 11020385 Combination therapy

Patent 11020385 was granted and assigned to Aerie Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
Aerie Pharmaceuticals
Aerie Pharmaceuticals
Date Filed
December 30, 2019
Date of Patent
June 1, 2021
Patent Applicant
Aerie Pharmaceuticals
Aerie Pharmaceuticals
Patent Application Number
16730015
Patent Citations
‌
US Patent 10882840 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
‌
US Patent 10112920 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
‌
US Patent 10174017 Dual mechanism inhibitors for the treatment of disease
‌
US Patent 10588901 Combination therapy
‌
US Patent 10654844 Dual mechanism inhibitors for the treatment of disease
‌
US Patent 10899714 6-aminoisoquinoline compounds
Patent Citations Received
‌
US Patent 12018012 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
‌
US Patent 11618748 Dual mechanism inhibitors for the treatment of disease
‌
US Patent 11707460 Ophthalmic compositions
0
‌
US Patent 11891376 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
‌
US Patent 11590123 Ophthalmic compositions
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11020385
Patent Primary Examiner
‌
James D. Anderson

Find more entities like US Patent 11020385 Combination therapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.